An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available. Mineralys Therapeutics announced that the U.S. FDA ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

RADNOR, PA — Mineralys Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its ...

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people with OSA don't sleep well, they are at a higher risk for motor vehicle ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Short-term HRV is significantly associated with poor daytime psychomotor vigilance performance among both men and women with ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.

Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...

Decreased blood flow of the optic nerve head (MA, MV, and MT measurements) was significantly correlated with increased OSA ...